Clinico-epidemiological evaLuation of mAcrolide use In Respiratory tract infections (CLAIR): a retrospective study

Prabhat Kumar Agrawal; Aishwarya Ashokkumar

doi:10.18203/2349-3933.ijam20263286

Authors

Prabhat Kumar Agrawal Care Hospital, Agra, Uttar Pradesh, India
Aishwarya Ashokkumar Medical Affairs, Abbott Primary Care, Abbott Healthcare Private Limited, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20263286

Keywords:

Macrolide, Upper and lower respiratory tract infections, Electronic medical records, Clinico-epidemiological characteristics, Symptom resolution

Abstract

Background: Respiratory tract infections (RTIs) are frequently seen in clinical practice, and macrolides are widely used for their management in India. However, real-world evidence (RWE) on prescribing patterns and clinical outcomes with macrolide use in RTIs is still limited. This study evaluated utilization patterns and effectiveness of macrolides for RTIs using an electronic medical records (EMR) database.

Methods: This retrospective, observational, EMR-based study analysed anonymized HealthPlix EMR data from January 2017 to June 2025. Adult patients (≥18 years) prescribed erythromycin, roxithromycin, azithromycin, or clarithromycin with a documented follow-up within 20 days were included. Propensity score matching (PSM) was applied for comparative effectiveness analysis between azithromycin and clarithromycin.

Results: A total of 78,499 eligible RTI patients were analyzed. Azithromycin (N=64,638) and clarithromycin (N=12,448) were the most frequently prescribed macrolides. Most patients were aged <60 years. Across macrolides, fever, cold, and cough predominated in upper RTIs (URTIs) whereas cough and dyspnea in lower RTIs (LRTIs), with bronchitis being the most common LRTI diagnosis. Hypertension and diabetes mellitus were the most common comorbidities. A 5–7-day regimen predominated across macrolides. Following PSM (12,448 patients per cohort of azithromycin and clarithromycin), overall symptom resolution was significantly higher with clarithromycin than azithromycin (72.36% vs 64.33%; p<0.001), with similar findings in URTI (74.98% vs 61.15%) and LRTI (69.86% vs 67.36%) subgroups. Symptom resolution remained high after switching to clarithromycin from other antibiotics.

Conclusions: This study provides RWE on macrolide prescribing patterns in RTIs and demonstrates higher symptom resolution with clarithromycin than azithromycin in routine clinical practice.

References

Reed KD. Respiratory tract infections. In: Tang YW, Sussman M, Liu D, Poxton I, Schwartzman J, eds. Molecular Medical Microbiology. 2nd ed. Oxford: Elsevier. 2015:1499-1506.

Sarmah N, Sarmah A, Das DK. A study on the microbiological profile of respiratory tract infection (RTI) in patients attending Gauhati Medical College & Hospital. Ann Int Med Dent Res. 2016;2(5):11-5.

Waghmode R, Jadhav S, Nema V. The burden of respiratory viruses and their prevalence in different geographical regions of India: 1970-2020. Front Microbiol. 2021;12:723850.

Pechère JC. The use of macrolides in respiratory tract infections. Int J Antimicrob Agents. 1993;3(1):53-61.

Patel PH, Hashmi MF. Macrolides. In: StatPearls. Treasure Island, FL: StatPearls Publishing. 2025.

Rubinstein E, Levy I. Macrolides as first line therapy in adult lower respiratory tract infections: pros and cons. Clin Microbiol Infect. 1996;1:223-6.

Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.

Nasr R, Rahal EA, Haddad C, Salameh P, Rahman AA. Impact of macrolide therapy on clinical outcomes in hospitalized pneumonia patients: a retrospective study from Lebanese hospitals. Sci Rep. 2025;15:43155.

Gusev AV, Zingerman BV, Tyufilin DS, Zinchenko VV. Electronic medical records as a source of real-world clinical data. Real-World Data Evid. 2022;2(2):8-20.

Talukdar N, Zhang X, Paithankar S, Wang H, Chen B. A survey of the use of EHR as real-world evidence for discovering and validating new drug indications. Drug Discov. 2025;30(12):104552.

Sharma BB, Singh S, Sharma KK, Sharma AK, Suraj KP, Mahmood T, et al. Proportionate clinical burden of respiratory diseases in Indian outdoor services and its relationship with seasonal transitions and risk factors: the results of SWORD survey. PLoS One. 2022;17(8):268216.

Jaakkola MS, Lajunen TK, Rantala AK, Nadif R, Jaakkola JJK. Occupation and occurrence of respiratory infections among adults with newly diagnosed asthma. BMC Pulm Med. 2023;23(140):1-12.

Xu Y, Qi L, Yang J, Duan Y, Jiang M, Sun Y, et al. Factors affecting the severity of respiratory infections: a hospital-based cross-sectional study. BMC Infect Dis. 2025;25(1):735.

Moitra R, Desai V, Raval M, Sonar B, Lokhandwala Z, Chakraborthy G, et al. A retro-prospective study of patients with a condition to URTI. Res J Pharm Technol. 2025;18(9):4323-8.

Mandell LA, Read RC. Infections of the lower respiratory tract. Antibiot Chemother. 2012;21:574-88.

Hansen LS, Lykkegaard J, Thomsen JL, Hansen MP. Acute lower respiratory tract infections: symptoms, findings and management in Danish general practice. Eur J Gen Pract. 2020;26(1):14-20.

Mahashur A. Management of lower respiratory tract infection in outpatient settings: focus on clarithromycin. Lung India. 2018;35(2):143-8.

Bade D, KG S, LJ K, MS R, VS H, AN P. A cross sectional study on prescription pattern of drugs in upper respiratory tract infections in a tertiary care hospital. Int J Basic Clin Pharmacol. 2020;9(2):271-5.

Llor C, Hansen MP, Lykkegaard J, Olsen J, Lindberg BH, Rebnord IK, et al. Duration of antibiotic treatment for respiratory tract infections in primary care. JAC Antimicrob Resist. 2025;7(1):28.

Bhargava S, Rawat DS, Khan MM, Bharathi MB, Ilambarathi M, Roy D, et al. Clarithromycin 500 mg extended-release in the management of patients with upper respiratory tract infection: results from a prospective, multicentre, single-arm and post-marketing observational study. Int J Otorhinolaryngol Head Neck Surg. 2025;11(6):666-74.

Dominic M, Srivastava R, Shah K, Naik SM, Rout K, Ray B, et al. Azithromycin in the management of upper respiratory tract infections (URTIs): Indian real-life experience. Infect Drug Resist. 2025;18:523-31.

Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. 1993;31(3):137-46.

Lima L, Antonio Pinto J, Nunes H, Paulo VC Cintra P, Onofre C, Gregório M Filho P, et al. Efficacy of azithromycin versus other antibiotics in the treatment of patients with upper respiratory tract infections. Clin Microbiol Infect Dis. 2021;6:1-4.

Gálvez-Múgica MA, Espinosa de los Monteros MJ, Gallego Sandín S, Novalbos J, Abad-Santos F. Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections. Rev Esp Quimioter. 2003;16(4):403-11.